These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35751566)

  • 1. The potential of developing a protective peptide-based vaccines against SARS-CoV-2.
    Shalash AO; Toth I; Skwarczynski M
    Drug Dev Res; 2022 Sep; 83(6):1251-1256. PubMed ID: 35751566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches.
    Safavi A; Kefayat A; Mahdevar E; Abiri A; Ghahremani F
    Vaccine; 2020 Nov; 38(48):7612-7628. PubMed ID: 33082015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
    Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
    Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of multi-epitope peptide-based vaccines against SARS-CoV-2.
    Lim HX; Lim J; Jazayeri SD; Poppema S; Poh CL
    Biomed J; 2021 Mar; 44(1):18-30. PubMed ID: 33727051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Next Generation Vaccines against SARS-CoV-2 and Variants of Concern.
    Al-Fattah Yahaya AA; Khalid K; Lim HX; Poh CL
    Viruses; 2023 Feb; 15(3):. PubMed ID: 36992333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoinformatics Approaches in Designing Vaccines Against COVID-19.
    Chakraborty A; Bayry J; Mukherjee S
    Methods Mol Biol; 2023; 2673():431-452. PubMed ID: 37258931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of B-Cell Epitopes for Eliciting Neutralizing Antibodies against the SARS-CoV-2 Spike Protein through Bioinformatics and Monoclonal Antibody Targeting.
    Lim HX; Masomian M; Khalid K; Kumar AU; MacAry PA; Poh CL
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Highly Conserved Peptide Vaccine Candidate Activates Both Humoral and Cellular Immunity Against SARS-CoV-2 Variant Strains.
    Gao F; Huang J; Li T; Hu C; Shen M; Mu S; Luo F; Song S; Hao Y; Wang W; Han X; Qian C; Wang Y; Wu R; Li L; Li S; Jin A
    Front Immunol; 2021; 12():789905. PubMed ID: 34950151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune and bioinformatics identification of T cell and B cell epitopes in the protein structure of SARS-CoV-2: A systematic review.
    Noorimotlagh Z; Karami C; Mirzaee SA; Kaffashian M; Mami S; Azizi M
    Int Immunopharmacol; 2020 Sep; 86():106738. PubMed ID: 32683296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of HLA-A*24:02-Restricted CTL Candidate Epitopes Derived from the Nonstructural Polyprotein 1a of SARS-CoV-2 and Analysis of Their Conservation Using the Mutation Database of SARS-CoV-2 Variants.
    Takagi A; Matsui M
    Microbiol Spectr; 2021 Dec; 9(3):e0165921. PubMed ID: 34937174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing an efficient multi-epitope vaccine displaying interactions with diverse HLA molecules for an efficient humoral and cellular immune response to prevent COVID-19 infection.
    Mahapatra SR; Sahoo S; Dehury B; Raina V; Patro S; Misra N; Suar M
    Expert Rev Vaccines; 2020 Sep; 19(9):871-885. PubMed ID: 32869699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T and B cell Epitope analysis of SARS-CoV-2 S protein based on immunoinformatics and experimental research.
    Chen Z; Ruan P; Wang L; Nie X; Ma X; Tan Y
    J Cell Mol Med; 2021 Jan; 25(2):1274-1289. PubMed ID: 33325143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus.
    Oberemok VV; Laikova KV; Yurchenko KA; Marochkin NA; Fomochkina II; Kubyshkin AV
    Inflamm Res; 2020 Sep; 69(9):801-812. PubMed ID: 32656668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning.
    Ong E; Wong MU; Huffman A; He Y
    Front Immunol; 2020; 11():1581. PubMed ID: 32719684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines.
    Reche PA
    Front Immunol; 2020; 11():586984. PubMed ID: 33178220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.